Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00750906 · ClinicalTrials.gov registry record
ECT/Succinylcholine: Biochemical, Serum and Cardiovascular Changes
A clinical trial, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- 13
- Enrollment target
NCT00750906: Clinical Trial study, sponsored by University of California, San Francisco.
NCT00750906 is a clinical trial that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00750906 was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- 13 participants
- Enrollment target
Study Summary
This study will be conducted to determine the pharmacodynamics, cardiovascular and biochemical effects of succinylcholine when given during electroconvulsive therapy. (ECT). This is a single center, prospective, study in patients who will be receiving ECT as indicated and prescribed by their psychiatrist. The study will be performed twice on each patient, 48-72 hours apart during consecutively scheduled ECT procedures.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2008-10 |
| Est. Completion | 2015-04-30 |
Why NCT00750906 stopped before completion
NCT00750906 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 13 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00750906 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00750906 about?
NCT00750906 is a clinical study titled "ECT/Succinylcholine: Biochemical, Serum and Cardiovascular Changes". This study will be conducted to determine the pharmacodynamics, cardiovascular and biochemical effects of succinylcholine when given during electroconvulsive therapy. (ECT). This is a single center, prospective, study in patients who will be receiving ECT as indicated and prescribed by their psychia...
What is the current status of trial NCT00750906?
This trial is currently terminated. The enrollment target is 13 participants. The study started on 2008-10. Estimated completion is 2015-04-30.
Who is sponsoring clinical trial NCT00750906?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia